PRYTEK
Aligned with Prytek’s strategy on building technologies and delivering managed services, it is building a new software testing arm by merging its own Technological company prooV™ with QAssure, a leading Asia based software testing company. After the merger Prytek will be the major shareholder providing software testing and prooV™ of Concept as a Service to the global market. Prytek is leading with the concept of BOPaaS (Business Operating Platform as Service) where it is lifting out entire operations from corporates providing them an entire operational solution based on Prytek technologies. The group operated in several sectors such as Financial Services, Cyber & Tech Education and HR sectors. This concept helps CEOs focus on their core business and outsource all banking regulations, software, and education requirements to Prytek.
QAssure and prooV™ announced their agreement to merge under the name of QAssure with Durairaj Dhanasekaran as its CEO. QAssure market-leading testing company head quartered in Singapore with a continuous testing technology platform and managed service capability. prooV™ owned by Prytek, is the first and only end-to-end proof-of-concept platform for third-party software, enabling global enterprises to evaluate and adopt the right new technologies safely, at a fraction of the time and cost. The combined services represent the most modern platform for accelerating open innovation and transforming software testing to keep pace with digital transformation. The combined entity will have a global presence with offices in Asia, the US, and EMEA. This integration will reflect the commitment to innovation and customer success that both companies share.
Andrey Yashunsky CEO of Prytek says “With this merger, we are creating deep tech proof of concept and digital assurance platform company that help accelerate and fast-track open innovation. With a strong implementation support centre based in Singapore, an R&D team based out of Israel and an offshore development team based out of India, we will be able to bring the best minds to build and deliver great technology and services addressing the global customer needs.”
Toby Olshanetsky, CEO and co-founder of prooV™ adds "We are very excited with this merger, in prooV™ we created the first PoC as a Service platform and now we create the first full end to end solution for technology & innovation adoption, using prooV™ and QAssure we provide a 360 offering: before, during and after the POC, enterprises can assess and test multiple technologies simultaneously to identify feature sets, scaling challenges, performance bottlenecks, and security risks before releasing an application to production".
According to Technavio, the global software testing services market has the potential to grow by USD 34.49 billion during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 12.39%. Enterprises have started focusing more on Quality Assurance, which can be gained by the implementation of agile solutions, leading to significant investments for the advancement of the latest quality assurance & software testing services.
About QAssure:
QAssure Technologies is an Independent Software Testing Company founded in 2005. Headquartered in Singapore with an expanding presence in India, Malaysia, Indonesia and the USA, QAssure Technologies focuses on specialized QA Engineering and Testing services with continuous autonomous validation and verification platform. QAssure Technologies brings together the essential combinations of value-driven robust domain knowledge, platforms and exceptional technical capabilities and burgeoning strategic alliances for leading IT solutions. Our expanding global footprint makes it possible for us to meet the software testing demands with versatile delivery models and specialized resources.
About Proov:
prooV™ is the first and only end-to-end proof-of-concept platform for third-party software, enabling global enterprises to evaluate and adopt the right new technologies safely, at a fraction of the time and cost. prooV consolidates the PoC process into one end-to-end ecosystem. With its simplified configuration and single point of integration, prooV enables companies to complete PoCs within days, not months, to run multiple PoCs simultaneously and to quickly evaluate different technology solutions from pre-screened vendors. prooV is the must-have solution for any organization looking to fast-track innovation.
About Prytek:
Prytek is a multinational technology group that builds deep technology and SaaS solutions through a BOPaaS (Business Operating Platform-as-a-Service) which is a combination of Deep Tech Solutions with Managed Services and Capital, providing the capability to lift out entire operations to create more efficient businesses of the future. Headed by industry experts, Prytek builds businesses and ecosystems in the Financial Services, Cyber & Tech Education and HR sectors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005855/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom